Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6 Suppl 15
|
| pubmed:dateCreated |
1996-7-15
|
| pubmed:abstractText |
In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2. The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration-time curve (AUC) of 5 using the Calvert formula. In levels 5 and 6 the carboplatin dose was targeted at AUCs of 6 and 7.5, respectively, combined with a fixed paclitaxel dose of 185 mg/m2. To date, 30 previously untreated patients, all with a good performance status (Eastern Cooperative Oncology Group 0 to 2) have been entered into this ongoing study. The dose-limiting toxicity of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia). Neurotoxicity was largely moderate. So far, 14 patients are evaluable for response; of these, eight (57%) showed objective (complete or partial) response and disease stabilized in six patients. No patient had disease progression. We conclude that the combination of paclitaxel 185 mg/m2 administered as a 3-hour infusion followed immediately by a 1-hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21-day schedule in the outpatient setting. The recommended dose for phase III studies is paclitaxel 185 mg/m2 and carboplatin AUC 6.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0093-7754
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
22
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
7-12
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:8643973-Adult,
pubmed-meshheading:8643973-Aged,
pubmed-meshheading:8643973-Agranulocytosis,
pubmed-meshheading:8643973-Ambulatory Care,
pubmed-meshheading:8643973-Antineoplastic Agents,
pubmed-meshheading:8643973-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:8643973-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8643973-Carboplatin,
pubmed-meshheading:8643973-Disease Progression,
pubmed-meshheading:8643973-Drug Administration Schedule,
pubmed-meshheading:8643973-Female,
pubmed-meshheading:8643973-Humans,
pubmed-meshheading:8643973-Infusions, Intravenous,
pubmed-meshheading:8643973-Leukopenia,
pubmed-meshheading:8643973-Middle Aged,
pubmed-meshheading:8643973-Ovarian Neoplasms,
pubmed-meshheading:8643973-Paclitaxel,
pubmed-meshheading:8643973-Peripheral Nervous System Diseases,
pubmed-meshheading:8643973-Remission Induction,
pubmed-meshheading:8643973-Safety,
pubmed-meshheading:8643973-Thrombocytopenia
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.
|
| pubmed:affiliation |
Frauenklinik, St-Vincentius-Krankenhäuser, Karlsruhe, Germany.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|